Prenetics Global Limited (NASDAQ:PRE - Get Free Report) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 34,500 shares, an increase of 46.2% from the May 15th total of 23,600 shares. Currently, 0.4% of the company's shares are short sold. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is currently 1.6 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new position in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent quarter. 25.01% of the stock is currently owned by institutional investors and hedge funds.
Prenetics Global Stock Up 23.3%
Shares of Prenetics Global stock traded up $1.75 during trading on Thursday, hitting $9.26. The stock had a trading volume of 380,483 shares, compared to its average volume of 20,617. Prenetics Global has a 1 year low of $3.09 and a 1 year high of $11.99. The stock has a 50 day simple moving average of $6.59 and a 200 day simple moving average of $5.58. The company has a market capitalization of $112.97 million, a PE ratio of -2.32 and a beta of 0.17.
Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) earnings per share for the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. The firm had revenue of $17.31 million for the quarter. As a group, equities analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Further Reading
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
